Xeljanz litigation
Claims allege that the arthritis drug Xeljanz increased the risks of blood clots, major cardiac events, and cancer, confirmed in a post-marketing safety trial.
Free case review
What the claims allege
The ORAL Surveillance trial found higher rates of major cardiovascular events and malignancy with tofacitinib than with TNF inhibitors, leading to boxed warnings across the JAK inhibitor class in 2021. Claims allege patients dosed at higher levels bore risks they were never told about.
Injuries named in the litigation
- Pulmonary embolism and DVT
- Heart attack and stroke
- Lymphoma and lung cancer
Who may qualify
If you took Xeljanz and suffered a blood clot, heart attack, stroke, or were diagnosed with lymphoma or lung cancer, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.